Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What’s In A PDUFA Reauthorization? Maybe These Issues…

11 Jul 2011

Related Content

Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011

07 Jul 2011

BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA

04 Jul 2011

Not Another FDAAA – Observers Expect Fewer FDA Reforms In PDUFA V

11 Jul 2011

PDUFA V Agreement Appears Set Between FDA And Industry

28 Apr 2011

CMS 2012 Budget Looks To Biosimilars, Brand/Generic Deals To Offset Costs

21 Feb 2011

House Approps Bill Would "Harden" Science Requirements For FDA Rules, Guidance

01 Jun 2011

Accelerated Approval Program’s Future Is On The Line At <i>Avastin</i> Hearing

23 May 2011

Drug Shortage Legislation Gains Momentum With Bipartisan House Bill

27 Jun 2011

Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves

20 Jun 2011

FDA Looks To Capitol Hill For New Authority For Globalization Plan

20 Jun 2011

FDA Steps Into <i>Makena</i> Pricing Dispute In The Name Of "Access"

04 Apr 2011

CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal

04 Apr 2011

Calls For Rx Imports Stay Alive: Montana, North Dakota Seek To Allow Residents To Buy From Canada

21 Apr 2010

"Mega-UFA" Is Behind Schedule; Combined User Fee Bill Will Be Difficult, But Still Expected

14 Feb 2011

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.